DES-Gamma Carboxy Prothrombin (DCP)/PIVKA II, Serum

DES-GAMMA CARBOXY PROTHROMBIN (DCP)/PIVKA II, SERUM Test

The Des-Gamma Carboxy Prothrombin (DCP) / PIVKA-II test measures an abnormal form of prothrombin produced when the liver cannot properly complete the vitamin K-dependent process involved in blood clotting. DCP is also known as PIVKA-II (Protein Induced by Vitamin K Absence or Antagonist-II).

The test is primarily used as a tumor marker in the evaluation and monitoring of hepatocellular carcinoma (HCC), the most common type of primary liver cancer. It may be used alongside AFP (alpha-fetoprotein), liver imaging, and other clinical investigations to provide a more complete assessment.

An elevated DCP level does not by itself confirm liver cancer, as levels can also be affected by vitamin K deficiency, certain medications, and other liver-related conditions. Results should therefore be interpreted by a healthcare provider in the context of the individual's clinical findings.

This Test is Recommended for Individuals:

• Individuals undergoing evaluation for suspected hepatocellular carcinoma (HCC)
• Patients with chronic liver disease or cirrhosis who require liver cancer surveillance, as advised
• Individuals with an abnormal AFP result requiring additional evaluation
• Patients with a previously diagnosed liver cancer who need treatment or disease monitoring
• Individuals being assessed for possible recurrence of hepatocellular carcinoma
• Patients undergoing evaluation of a liver mass along with imaging and other tumor markers

FAQs

1. What does the DCP/PIVKA-II test detect?
It measures an abnormal form of prothrombin called DCP or PIVKA-II. Elevated levels can be associated with hepatocellular carcinoma and may provide additional information during liver cancer evaluation.

2. Does a high DCP level mean that a person has liver cancer?
No. An elevated DCP level does not confirm cancer on its own. Vitamin K deficiency, certain medications, and other liver conditions can also affect DCP levels. Imaging and other laboratory tests may be needed for diagnosis.

3. Is DCP/PIVKA-II the same as AFP?
No. DCP/PIVKA-II and AFP are different liver tumor markers. They may be used together because some hepatocellular carcinomas may produce one marker more than the other. Combining tumor markers with appropriate imaging can provide a more comprehensive evaluation.